Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform

Area of Science:

• Pharmacology
• Transplant Medicine
• Biomedical Engineering

Background:

• Immunosuppressive drugs like tacrolimus have narrow therapeutic ranges, leading to dosing challenges in transplant patients.
• Current physician-guided dosing often results in deviations from target drug levels, especially post-surgery.
• Personalized dosing strategies are needed to improve patient safety and reduce hospital stays.

Purpose of the Study:

• To introduce and evaluate the parabolic personalized dosing (PPD) platform for optimizing tacrolimus therapy.
• To compare PPD-guided dosing with standard care in a pilot randomized controlled trial.
• To assess PPD's ability to maintain tacrolimus blood trough levels within therapeutic ranges.

Main Methods:

• Developed the PPD platform, a personalized dosing system based on a second-order algebraic equation.
• Used patient-specific clinical data, including tacrolimus blood concentrations, to calibrate PPD coefficients.
• Conducted a pilot randomized controlled trial comparing PPD with standard physician-guided dosing for tacrolimus.

Main Results:

• PPD effectively maintained tacrolimus blood trough levels within target ranges in prospectively treated patients.
• Retrospective analysis showed PPD-optimized dosing improved tacrolimus and prednisone management in control patients.
• PPD minimized the need for dose recalibration following changes in medication regimens.

Conclusions:

• The PPD platform offers a personalized, phenotype-driven approach to tacrolimus dosing in transplant recipients.
• PPD demonstrates potential for improving immunosuppression management, reducing adverse events, and facilitating earlier patient discharge.
• The PPD system's adaptability suggests broader applications beyond transplantation, including in oncology, infectious diseases, and cardiovascular medicine.